Login / Signup

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.

Graeme L FraserBarbara Obermayer-PietschJoop LavenGeorg GriesingerAxelle PintiauxDirk TimmermanBart C J M FauserChristopher LademacherJean CombalbertHamid R HoveydaSteven Ramael
Published in: The Journal of clinical endocrinology and metabolism (2021)
Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS.
Keyphrases
  • polycystic ovary syndrome
  • randomized controlled trial
  • insulin resistance
  • metabolic syndrome
  • type diabetes
  • skeletal muscle
  • systematic review
  • clinical trial
  • replacement therapy